HH
HBL Hadasit Bio Holdings
Venture CapitalModerateHBL Hadasit Bio Holdings is the medical research center of the Hadassah University Hospital.
8
Investments
4
Exits
—
AUM
50.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for HBL Hadasit Bio Holdings.
Investment Thesis & Strategy
HBL Hadasit Bio Holdings invests in various stages of biopharma, biotech, and life science companies, specifically those emerging from the Hadassah University Hospital's medical research center.
Investment Activity
Deals per year over the last 15 years
2
20070
20080
20090
20101
20110
20120
20130
20140
20151
20161
20173
20181
20191
20202
2021Portfolio Companies
Selected investments from their portfolio of 8 companies
N
NanoGhost
Biotech · Series A, 2021
N
Nectin Therapeutics
Biotech · Series A, 2021
I
Inspira Technologies
Healthcare · Growth, 2020
G
GentleVision
Healthcare · Series A, 2019
P
Pepticom
Biotech · Series A, 2018
X
XACT Robotics
Healthcare · Series B, 2018
I
Innovision
Healthcare · Series A, 2018
E
EyeYon Medical
Healthcare · Series A, 2017
T
Theranica
Healthcare · Series B, 2016
C
CartiHeal
Healthcare · Growth, 2011
B
Brainsway
Healthcare · Growth, 2007
C
CollPlant Biotechnologies
Biotech · Growth, 2007
Notable Exits
CompanyTypeYearValue / Acquirer
BrainStorm Cell TherapeuticsIPO2017—
Therapix BiosciencesIPO2017—
CollPlant BiotechnologiesIPO2013—
BioLineRxIPO2007—
Frequently Asked Questions
HBL Hadasit Bio Holdings focuses on Series A, Series B, Series C+ stage investments.